The ‘new, old kids’ on the biotech block unveil a $350M stealth science fund. And they’re going very, very early

Richard Lim and his two co-founders at Cure Ventures have some biotech stories to tell.

Lim recalls the time some 17 years ago he and Lou Tartaglia were going to start something — but then Tartaglia jumped to Third Rock as Kevin Starr and Bob Tepper were ramping things up, with roles at Editas and Agios. He later moved to 5AM. Then there are tales of Dave Fallace’s biotech-naming role at Juno and Denali when Alaska’s most iconic locations provided names for two of his more notable startups at the Alaska Permanent Fund.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE

ENDPOINTS CAREERS

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

view job offer post your job now

TRENDING NOW

The ‘new, old kids’ on the biotech block unveil a $350M stealth science fund. And they’re going very, very early

This article is for premium subscribers only

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

The next generation of AI biotechs is here. Can they deliver on the hype?

Sanders presses pharma leaders to change stance on Pandemic Accord proposals

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

The ‘new, old kids’ on the biotech block un­veil a $350M stealth sci­ence fund. And they’re go­ing very, very ear­ly

This article is for premium subscribers only

more like this

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py R&D fa­cil­i­ty as it elim­i­nates jobs and costs

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Sanders press­es phar­ma lead­ers to change stance on Pan­dem­ic Ac­cord pro­pos­als

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

The ‘new, old kids’ on the biotech block unveil a $350M stealth science fund. And they’re going very, very early

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

The next generation of AI biotechs is here. Can they deliver on the hype?

Sanders presses pharma leaders to change stance on Pandemic Accord proposals

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag